Zimbabwe has rejected a significant American health deal worth $367m (272 million pounds) over five years over the United States' request for confidential information.
This rejection came to light following a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government representative later stated that the United States was seeking genetic material for scientific study and commercial gain but was unwilling to guarantee the resulting advantages from any future treatments.
"We will now turn to the challenging and unfortunate process of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had donated over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for continued negotiations to reach a deal suitable to both sides so the country's vital HIV treatment initiative can continue.
Broader Background
This rejection comes after a comparable situation in Kenya, where a court suspended a similar health funding agreement after concerns were raised about the security of Kenyans' medical information.
After resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump argued its expenditure was "wasteful" and his government was pursuing government-to-government agreements to boost transparency and accountability.
According to statements, 16 African countries have so far agreed to these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation could have provided immense benefits for the people of Zimbabwe, especially the 1.2 million currently receiving antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, without any corresponding promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"In essence, our nation would supply the raw materials for scientific discovery without any assurance that the resulting innovations would be accessible to our population should a future pandemic arise."
National Interest and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending structures already established through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to deal with future pandemics.
"This framework is intended to ensure that when a nation provides its samples, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to develop them."
These objections over the US deal "must not be interpreted as opposition to America," he added.
"We encourage ongoing dialogue with our American counterparts on how future co-operation could be structured in a manner that respects the sovereignty and interests of both nations."
Medical Community Response
Medical experts expressed it recognised the government's concerns, but recommended that talks need to persist given that a large portion of the nation's Aids initiatives relied on external financing.
"If specific concerns exist, such as those involving data governance or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," it commented.
The halted deal emphasises the continuing debate between receiving vital foreign assistance and safeguarding national sovereignty in an ever more data-driven world.